Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Disease-Modifying Adjunctive Therapy (DMAT) in Osteoarthritis – The Biological Effects of a Multi-mineral Complex, LithoLexal®

Version 1 : Received: 19 October 2021 / Approved: 20 October 2021 / Online: 20 October 2021 (22:49:47 CEST)

A peer-reviewed article of this Preprint also exists.

Eriksen, E.F.; Lech, O.; Nakama, G.Y.; O’Gorman, D.M. Disease-Modifying Adjunctive Therapy (DMAT) in Osteoarthritis—The Biological Effects of a Multi-Mineral Complex, LithoLexal® Joint—A Review. Clin. Pract. 2021, 11, 901-913. Eriksen, E.F.; Lech, O.; Nakama, G.Y.; O’Gorman, D.M. Disease-Modifying Adjunctive Therapy (DMAT) in Osteoarthritis—The Biological Effects of a Multi-Mineral Complex, LithoLexal® Joint—A Review. Clin. Pract. 2021, 11, 901-913.

Journal reference: Clin. Pract. 2021, 11, 104
DOI: 10.3390/clinpract11040104

Abstract

Modern advances in molecular medicine have led to reframing osteoarthritis as a metabolically active, inflammatory disorder with local and systemic contributing factors. According to the ‘inflammatory theory’ of osteoarthritis, immune response to an initial damage is the key trigger that leads to progressive joint destruction. Several intertwined pathways are known to induce and govern articular inflammation, cartilage matrix degradation, and subchondral bone changes. Effective treatments capable of halting or delaying the progression of osteoarthritis remain elusive. As a result, supplements such as glucosamine and chondroitin sulphate are commonly used despite the lack of scientific consensus. A novel option for adjunctive therapy of osteoarthritis is LithoLexal®, a marine-derived, mineral-rich extract, that exhibited significant efficacy in clinical trials. LithoLexal® has a lattice microstructure containing a combination of bioactive rare minerals. Mechanistic research suggests that this novel treatment possesses various potential disease-modifying properties, such as suppression of nuclear factor kappa-B, interleukin 1β, tumour necrosis factor α, and cyclooxygenase-2. Accordingly, LithoLexal® can be considered a disease-modifying adjunctive therapy (DMAT). LithoLexal® monotherapy in patients with knee osteoarthritis has significantly improved symptoms and walking ability with higher efficacy than glucosamine. Preliminary evidence also suggests that LithoLexal® may allow clinicians to reduce the dose of nonsteroidal anti-inflammatory drugs in osteoarthritic patients by up to 50%. In conclusion, the multi-mineral complex, LithoLexal®, appears to be a promising candidate for DMAT of osteoarthritis, which may narrow the existing gap in clinical practice.

Keywords

Osteoarthritis; LithoLexal; Lithothamnion; Disease-modifying adjunctive therapy; Anti-inflammatory agents; Cytokine inhibitors

Subject

MEDICINE & PHARMACOLOGY, Other

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.